Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PepGen
Biotech
FDA hits pause on another of PepGen's muscular dystrophy trials
The CONNECT2-EDO51 trial is designed to test PepGen’s PGN-EDO51 exon-skipping therapy over 25 weeks in patients with DMD.
James Waldron
Dec 16, 2024 9:45am
BioMarin builds exec team with biotech vets—Chutes & Ladders
Aug 23, 2024 8:30am
J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders
Jun 14, 2024 8:30am
PepGen gains a little pep in its step as FDA clears trial hold
Oct 12, 2023 7:00am
Awaiting FDA letter, PepGen oligonucleotide no closer to clinic
Jun 14, 2023 9:05am
FDA blocks PepGen's attempt to get 2nd oligonucleotide to clinic
May 31, 2023 8:11am
